Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Non Operating Income (2018 - 2023)

UroGen Pharma (URGN) has disclosed Non Operating Income for 5 consecutive years, with -$715000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Income fell 79.65% year-over-year to -$715000.0, compared with a TTM value of -$689000.0 through Dec 2023, down 161.98%, and an annual FY2025 reading of $605000.0, up 176.26% over the prior year.
  • Non Operating Income was -$715000.0 for Q4 2023 at UroGen Pharma, down from $71000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $989000.0 in Q1 2019 and bottomed at -$715000.0 in Q4 2023.
  • Average Non Operating Income over 4 years is -$8923.1, with a median of -$15000.0 recorded in 2023.
  • Peak annual rise in Non Operating Income hit 331.25% in 2022, while the deepest fall reached 416.88% in 2022.
  • Year by year, Non Operating Income stood at $989000.0 in 2019, then tumbled by 107.79% to -$77000.0 in 2021, then crashed by 416.88% to -$398000.0 in 2022, then crashed by 79.65% to -$715000.0 in 2023.
  • Business Quant data shows Non Operating Income for URGN at -$715000.0 in Q4 2023, $71000.0 in Q3 2023, and -$30000.0 in Q2 2023.